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ew Light on an
ld Problem
hotodynamic Therapy for
therosclerosis*
ames E. Muller, MD, FACC
urlington, Massachusetts
he study by Waksman et al. (1) in this issue of the Journal
dds to the data indicating that photodynamic therapy
PDT) might provide a novel means to stabilize atheroscle-
otic plaques. The results clearly demonstrate that PDT can
arkedly diminish the macrophage content of lesions in-
uced by injury and cholesterol-feeding in a 5-week rabbit
odel. The area of the plaque occupied by macrophages, an
mportant component of the inflammation that occurs in
laques suspected to be vulnerable to rupture, was reduced
y 98% at 7 days after PDT.
See page 1024
Although PDT is widely used for treatment of dermato-
ogic and cancer patients, it is not in general use in the field
f cardiology and hence is unfamiliar to many cardiovascular
pecialists. The technique is based on the localization and
ubsequent activation of a potentially destructive photosen-
itizing agent in a target of interest (2). The agent is
ctivated by exposure to a small amount of light (nonion-
zing and nonthermal electromagnetic energy) that, in the
resence of oxygen, creates reactive oxygen species that
estroy cells in the area. Specificity of destruction can be
chieved by: 1) selective application of the PDT agent;
) selective uptake of the agent; and 3) selective exposure of
issue to the activating light.
These desirable attributes have led to the clinical application
f PDT for the treatment of acne, nonmelanoma skin cancer,
arrett’s esophagus, and wet macular degeneration (2).
An impressive feature of the current study of cardiovas-
ular use is that the Miravant photosensitizer compound
MV0611) destroyed macrophages (and smooth muscle
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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aid employee of the company.ells) without damaging the structural integrity of the
essel—by 28 days the tissue was intact, and repopulation
ith smooth muscle cells was well under way.
The findings of the current study are in accord with prior
tudies in animals with experimental atherosclerosis (2).
atoh et al. (3) tested a different photosensitizer in rabbits
nd also found that most intimal cells were destroyed at 7
ays. A study in atherosclerotic miniswine provided a
arning that higher doses of light could produce damage to
he media (4). Tawakol et al. (5) demonstrated that a
hotosensitizer designed to be taken up selectively by the
acrophage scavenger receptor could accumulate in macro-
hages without accumulating in smooth muscle cells. Ha-
ase et al. (6), with a rabbit model similar to that employed
n the current study, demonstrated that motexafin lutetium
Antrin, Pharmacyclics, Inc., Sunnyvale, California) local-
zed in plaque and its activation produced selective depletion
f macrophages.
Studies of PDT for treatment of atherosclerosis in pa-
ients are quite limited. In 1999, Jenkins et al. (7) used
-aminolevulinic acid with percutaneous transluminal cor-
nary angioplasty for restenosis in femoral arteries; no
dverse events were noted in the uncontrolled experience.
ntrin was tested by Kereiakes et al. (8) in a phase 1 study
f 75 patients undergoing coronary stenting. The uncon-
rolled results showed no coronary complications and iden-
ified safe doses of drug and light; 1 patient developed an
rythematous cutaneous reaction and several others experi-
nced rashes and paresthesias, which were self-limited.
Although the current study supports continued research
ith PDT for atherosclerosis, it has limitations as noted by
he authors. Given the extensive pre-existing studies in
nimals, this study is primarily a confirmation of prior
ndings. It does provide a novel emphasis on plaque
tabilization, as opposed to plaque ablation or prevention of
estenosis. Observations were completed at 28 days, and the
ong-term outcome of such extensive destruction of cells has
ot yet been studied. The agent, MV0611, requires activa-
ion by green light (542 nm), which in turn requires removal
f blood; other agents, such as Antrin, which is activated by
ed light (732 nm), are more easily activated through blood.
inally, MVO611 has not been cleared for administration to
umans and is therefore considerably behind Antrin and
ther PDT agents in development for clinical use.
There are also limitations of the cholesterol-fed, balloon-
njured, 5-week rabbit model. The lesions produced in this
anner are macrophage-rich and are similar to the human
esions described as “pathological intimal thickening.” They
re not equivalent to the lipid-core plaques associated with
oronary syndromes in patients. The diabetic, cholesterol-
ed pig does develop lipid-core lesions and would be an
xcellent model for future studies of the effect of a PDT
gent on plaques suspected to be vulnerable to rupture (9).
Finally, there are clinical limitations to the application to
umans of any of the current PDT approaches. All require
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Editorial Comment September 16, 2008:1033–4ntravascular illumination and hence are limited to use
uring invasive procedures. The requirement that the PDT
gent be administered 8 to 24 h before activation will hinder
sage in acute coronary syndromes, and the need of some
gents for 10 min or more of illumination will slow
atheterization laboratory procedures. Finally, there are the
ssues of cutaneous and neural side effects, which seem to be
elatively minor, and the need for avoidance of bright light
fter the procedure.
With these inherent limitations and the unresolved re-
earch issues discussed in the preceding text, it is appropri-
te to question the wisdom of expending additional efforts
o develop PDT for the treatment of atherosclerosis. Be-
ause stenting resolved the problem of obstruction and
rug-eluting stents diminished interest in the role of PDT
o prevent restenosis, there are at present no commercial
fforts under way to develop either MV0611 or Antrin for
linical use.
It is in this negative setting that the emphasis of Waks-
an et al. (1) on PDT for plaque stabilization provides a
ew perspective and suggests a potentially valuable role for
DT. The potential role is based on the continued occur-
ence of cardiac events after stenting and the pathophysiol-
gy responsible for such events. In the year after stenting,
pproximately 10% of patients experience an event from a
esion not considered stenotic enough for stenting at the
ime of the initial procedure (10).
Pathologic studies indicate that the substrates for the
ajority of these events are likely to be lipid-core plaques at
ocations other than that of the original culprit lesion. Most
atients undergoing stenting have only 1 or 2 such lipid-
ore lesions (counting the culprit), but as many as 8 have
een documented, and they might occupy over 30 mm of
oronary length (11). Natural history studies are in progress
o determine whether these lesions are indeed the sites
esponsible for future events.
If nonstenotic, inflamed lipid-core lesions are proven to
ause subsequent events—to be vulnerable plaques, as sus-
ected— or if the presence of such plaques identifies pa-
ients at higher risk of subsequent events—vulnerable
atients—then what is optimal preventive therapy? Unfor-
unately, the optimal medical therapy currently available
ith statins and other agents prevents only 20% to 30% of
ubsequent events. If individual vulnerable plaques can be
dentified, then perhaps prophylactic stenting of such le-
ions (with improved stents) would be effective. If vulnera-
le plaques cannot be found but vulnerable patients can be
dentified, then the length of artery requiring treatment
ould be extensive, and the complications of prophylactic
tenting would be increased.
K
sIt is in this quest for prevention of events after stenting of
 culprit lesion that intracoronary PDT might have a useful
ole. The patient is already undergoing an invasive proce-
ure, so the invasive nature of intravascular PDT is not an
mpediment. If inflamed nonstenotic plaques are found to
e the cause of future events (i.e., to be vulnerable plaques),
hen their selective treatment with PDT might be optimal
herapy. If vulnerable plaques cannot be identified but
ulnerability of longer regions of artery can be detected,
DT might provide a convenient method to passivate a
engthier span of coronary atherosclerosis. In either case,
ontinued studies, such as those conducted by Waksman
t al. (1), are of value in developing this potentially impor-
ant novel approach to stabilization of atherosclerotic
laques.
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